Joshua Brody
Developed in situ vaccination, turning a single injected lymphoma tumour into a vaccine against the rest.
Haematologist-oncologist whose Flt3L, radiation and TLR-agonist in situ vaccine approach induced systemic responses in lymphoma; leads bispecific and CAR-T trials.
| Title | Journal | Year |
|---|---|---|
| Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination | Nature Medicine | 2019 |
Pages like this
not linked directly; found by shared links- PersonNina Bhardwaj
Shares The Mount Sinai Hospital / Tisch Cancer Institute, Off-the-shelf cancer vaccines.
- TrialSTARGLO
Shares T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
- IdeaHead-to-head bispecific vs CAR-T in second-line LBCL
Shares T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
- ProductOdronextamab
Shares T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
- IdeaTurn one tumour into a vaccine to treat all the others
Shares The Mount Sinai Hospital / Tisch Cancer Institute, Diffuse large B-cell lymphoma.
- TermRichter transformation
Shares T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
- InstitutionUniversity Hospital Southampton / Centre for Cancer Immunology
Shares Off-the-shelf cancer vaccines, Diffuse large B-cell lymphoma.
- InstitutionOxford Cancer – Oxford University Hospitals and University of Oxford
Shares Off-the-shelf cancer vaccines, T-cell engagers (bispecific).